Connect with us
European Gaming Congress 2024

Uncategorized

PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 – Exclusive Report by InsightAce Analytic

Published

on

parp-inhibitors-market-to-reach-over-usd-10.31-billion-by-the-year-2031-–-exclusive-report-by-insightace-analytic

 
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global PARP Inhibitors Market Size, Share & Trends Analysis Report By Product (Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), Talazoparib (Talzenna), Veliparib, Other Pipeline Drugs), By Indication (breast cancer, ovarian cancer, and prostate and pancreatic cancer), Region, Market Outlook And Industry Analysis 2031″
The global PARP Inhibitors market is estimated to reach over USD 10.31 billion by 2031, exhibiting a CAGR of 14.78% during the forecast period for 2023-2031.
PARP Inhibitors Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2022

USD 3,071.9 Mn

Advertisement

Revenue Forecast In 2031

USD 10,317.3 Mn

Growth Rate CAGR

CAGR of 14.78% from 2023 to 2031

Quantitative Units

Advertisement

Representation of revenue in US$ Mn and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Advertisement

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product and Indication

Regional Scope

Advertisement

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Get Sample copy of the Global PARP Inhibitors Market Report at: https://www.insightaceanalytic.com/request-sample/1169 
PolyaDP-ribose polymerase (PARP) inhibitors consist of extended chains composed of 17 enzymes, which enable the transport of numerous ADP-ribose units to the intended target proteins. When DNA is harmed by various circumstances, including using multiple anti-cancer medications and exposure to UV radiation, this aids in its restoration.
PARP inhibitors prevent an enzyme required for the repair of DNA single-strand breaks. Inhibition of this DNA repair enzyme can cause cell death in cancer cells that lack alternative DNA repair pathways. Hence, these inhibitors are widely utilized to treat a variety of malignancies, including ovarian and breast cancer.
The market growth is predicted to be fueled by leading players’ emphasis on research and development to create new products. Furthermore, the global market for PARP inhibitors is projected to grow as cancer incidence rates.
However, market expansion is propelled by the strategic developments of market participants. The market for PARP inhibitors is anticipated to expand due to increased demand resulting from their efficacy. Significant factors expected to contribute to the market’s substantial growth potential for PARP inhibitors are an increased emphasis by governments of developing countries on improving healthcare accessibility and a heightened awareness of contemporary technologies.
List of Prominent Players in the PARP Inhibitors Market:

Johnson & Johnson Services, Inc.
Merck KGaA
GSK plc.
Pfizer Inc.
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.
Artios Pharma
Genentech, Inc.
Karyopharm Therapeutics Inc.
Repare Therapeutics Inc
ONO PHARMACEUTICAL CO., LTD
Jiangsu Hengrui Pharma Co., Ltd.
Bristol-Myers Squibb Co
AstraZeneca plc
Checkpoint Therapeutics, Inc.
Eisai Co., Ltd.
IMPACT Therapeutics
JEIL PHARMA CO.,LTD.
Kyowa Kirin Co., Ltd
SyntheX

Advertisement

Market Dynamics:
Drivers-
Over the forecast period, the global market for PARP inhibitors is anticipated to expand due to the rising cancer incidence and the demand for pharmaceuticals. In addition, PARP inhibitors and chemotherapeutic agents may be utilized to inhibit the proliferation of cancer cells. It is anticipated that expanding research and development in cancer treatment will present manufacturers with advantageous prospects to introduce novel medications into the PARP inhibitor market.
Challenges:
PARP inhibitor side effects impede the market’s growth. Strict regulations will prevent resistance to PARP inhibitors, another issue impeding market expansion. However, high expenses associated with clinical trials, stringent regulations, and frequent product recalls limit the market.
Regional Trends:
In the near future, the North American market for PARP Inhibitors is anticipated to account for a substantial portion of the revenue and expand at a rapid CAGR due to the region’s advanced healthcare industry and substantial healthcare expenditures. The accessibility of authorized PARP inhibitors and the rising incidence of solid tumors in the region are two significant factors influencing the market’s expansion. The demand for PARP inhibitors in the region is anticipated to increase over the forecast period due to the introduction of new products, the presence of significant market participants that emphasize research and development, and a rise in cancer incidence. Besides, Asia Pacific had a substantial share in the PARP Inhibitors market because of the expanding population. Due to increasing R&D efforts and healthcare spending, the Asia Pacific market is predicted to expand more quickly. It is anticipated that the demand for PARP inhibitors will grow due to investments made by large corporations in developing nations to meet unmet needs and strengthen their competitiveness.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/1169
Recent Developments:

In February 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium, taking place February 16-18.
In October 2023, Merck, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904.
In October 2023, Merck, announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167. The agreement also includes an option to an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904.

Segmentation of PARP Inhibitors Market-
By Drug Type-

Niraparib (Zejula)
Olaparib (Lynparza)
Rucaparib (Rubraca)
Talazoparib (Talzenna)
Veliparib
Other Pipeline Drugs

By Indication-

Advertisement

Ovarian Cancer
Breast cancer
Prostate and Pancreatic Cancer

By Region-
North America–

The US
Canada
Mexico

Europe–

Germany
The UK
France
Italy
Spain
Rest of Europe

Advertisement

Asia-Pacific–

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Latin America–

Brazil
Argentina
Rest of Latin America

 Middle East & Africa–

Advertisement

GCC Countries
South Africa
Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/1169
Why should buy this report:
Ø  To receive a comprehensive analysis of the prospects for global PARP Inhibitors market
Ø  To receive industry overview and future trends of global PARP Inhibitors market
Ø  To analyse the PARP Inhibitors market drivers and challenges
Ø  To get information on PARP Inhibitors market size value (US$ Mn) forecast till 2031
Ø  Major Investments, Mergers & Acquisition in global PARP Inhibitors market industry
Other Related Reports Published by InsightAce Analytic:
PD-1 and PD-L1 Inhibitors Market
Oncology Drug Discovery & Development Market
Bruton Tyrosine Kinase (BTK) Inhibitors Market
Next Generation Complement Therapeutics Market
KRAS Inhibitors Market
The post PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 – Exclusive Report by InsightAce Analytic appeared first on HIPTHER Alerts.

Continue Reading
Advertisement

Uncategorized

Hugues Péribère of Overseed Named in the 2024 Business Worldwide Magazine CEO Awards

Published

on

hugues-peribere-of-overseed-named-in-the-2024-business-worldwide-magazine-ceo-awards

 
Hugues Péribère, CEO of Overseed, has been named CEO of the Year in Europe’s Biopharmaceutical Industry in the 2024 Business Worldwide CEO Awards.
Internationally acclaimed for celebrating the most esteemed C-level executives, the awards recognise outstanding leaders across a wide range of industries. The focus is on the visionaries—CEOs, Managing Directors, and senior managers—whose leadership drives their organisations to success.
Péribère’s achievement highlights his exemplary work in leading Overseed, a pioneering force in France’s biopharmaceutical landscape, particularly in medical cannabis production. Under his leadership, Overseed has emerged as a frontrunner in the development of pharmaceutical-grade medical cannabis in France. With expertise in genetics, agronomy, and pharmaceutical chemistry, Overseed is set to become the first French manufacturer of 100% cannabis-based medicines, helping to shape the future of healthcare as France prepares for the legalisation of medical cannabis in 2025.
Péribère, an agronomic engineer with a strong background in managing specialised plant cultivation across Europe, founded Overseed in 2020. His deep understanding of supply chains, geopolitical and climatic issues related to production, and the medical benefits of cannabis has positioned Overseed as a key player in addressing critical public health needs through innovative cannabinoid treatments.
The company is dedicated to producing high-quality, pharmaceutical-grade cannabinoid products that meet the needs of patients suffering from conditions such as chemotherapy side effects, multiple sclerosis, and neuropathic pain. By focusing on national sovereignty and producing its treatments within France, Overseed ensures reliable patient access and mitigates risks of supply chain disruptions.
“Overseed is not just about responding to market demands; we are building an industry that will serve the public health of France for years to come,” said Péribère. “This award reflects our team’s commitment to advancing medical research and setting a high standard for cannabinoid-based therapies.”
Overseed has been a leader in research and development since 2021, when it became the first company to receive R&D authorization for the cultivation of Cannabis sativa L. in France. The company’s partnerships with institutions such as the CNRS/CBM and the University Hospital of Orléans have enabled critical research into expanding the therapeutic use of cannabis.
With plans to further scale its operations, Overseed is set to meet the growing demand for medical cannabis as legalisation approaches. Overseed’s diverse product portfolio, including CBD- and THC-dominant oils, will address the specific needs of patients suffering from conditions approved for medical cannabis treatment.
To learn more about Overseed’s journey and its pioneering work in medical cannabis production, visit www.overseed.fr.
Further information about the Business Worldwide CEO Awards can be found at https://www.bwmonline.com/2024-ceo-awards-winners/
The post Hugues Péribère of Overseed Named in the 2024 Business Worldwide Magazine CEO Awards appeared first on HIPTHER Alerts.

Continue Reading

Uncategorized

The Readyverse Debuts AI Tool “Promptopia” for Limitless Creativity in Gaming

Published

on

the-readyverse-debuts-ai-tool-“promptopia”-for-limitless-creativity-in-gaming

Readyverse Studios, a leading next-gen game publisher, proudly unveils Promptopia, an AI-powered generative creation tool that brings unmatched creative possibilities to the digital world. Making its debut at the Blockworks tech conference Permissionless III, Promptopia is an innovative sandbox experience where players can bring their imaginations to life by creating game-ready objects, environments, music, and more with the simplest of text prompts.
Unlocking  a new level of digital creativity, Promptopia combines multiplayer gameplay with real-time AI asset generation allowing users to build, share, and play in a world shaped by their own ideas. By harnessing the latest in AI technology, Promptopia shatters the boundaries between creators and players, transforming anyone into a game designer with ease.

Promptopia provides players with limitless creative freedom, integrating AI tools in real time to generate 3D assets and environments within The Readyverse platform, which already includes a variety of globally recognized IP, such as Reebok, Cool Cats, DeLorean and Ready Player One. From stunning scenery to interactive objects, Promptopia opens a world of possibilities in a social, collaborative virtual environment. 
“Promptopia is a new experimental game experience that allows us to see how generative AI and game mechanics can come together in interesting ways,” said Readyverse Studios Co-Founders Aaron McDonald and Shara Senderoff. “Promptopia builds the groundwork for the UGC experience in The Readyverse. We’re giving players the ability to make what’s in their mind an immediate reality, and have prompt engineering become part of a deeper immersive gameplay experience. We’ve prioritized creativity and fun at the core so the interactive user experience can be appreciated by every gamer as they bring their imaginations to life through gameplay. It’s a blank canvas waiting for your ideas to be incorporated.”
While many tech giants are exploring the possibilities of AI, Promptopia from Readyverse Studios sets a new standard by offering an unparalleled level of integration within gameplay. As part of The Readyverse ecosystem, and using the novel “Altered State” generative 3D model developed by Futureverse and music AI platform Jen, players can generate real-time, game-ready assets, environments, and soundtracks through simple text prompts. Promptopia is designed to democratize game creation, allowing anyone to become a creator regardless of their technical skill level.
The post The Readyverse Debuts AI Tool “Promptopia” for Limitless Creativity in Gaming appeared first on HIPTHER Alerts.

Continue Reading

Uncategorized

The Rise of AI Drives 9 Fold Surge in Liquid Cooling Technology

Published

on

the-rise-of-ai-drives-9-fold-surge-in-liquid-cooling-technology

AI servers, driven by Nvidia’s GB200 superchip, have experienced significant growth. The cutting-edge B200 chip, due to its high thermal design power, requires direct-to-chip cooling. Supermicro announced that it had shipped over 2000 direct-liquid-cooled AI server racks by the end of August 2024, and it has expanded its manufacturing capacity to 5000 racks per month. Supermicro reported that it has around 75% of the liquid-cooled AI server rack market, and IDTechEx believes that this production capacity expansion will lead to a surge in liquid-cooled server racks, as well as the number of cold plates. The projections for the number of cold plates for AI servers in IDTechEx’s new report, “Thermal Management for Data Centers 2025-2035: Technologies, Markets, and Opportunities”, align with Supermicro’s latest announcement.
IDTechEx believes that this production capacity expansion is expected to drive a rapid increase in the deployment of liquid-cooled racks across the AI and high-performance computing (HPC) sectors, along with a notable rise in the use of cold plates. Cold plates are integral to direct-liquid-cooling systems, as they are responsible for absorbing and dissipating the significant heat generated by high-performance chips like Nvidia’s B200. IDTechEx’s recent research into thermal management for data centers echoes Supermicro’s projections, highlighting the increasing importance of liquid cooling technologies in managing the heat loads associated with next-generation AI and HPC hardware.
Direct-to-chip (D2C) cooling, also known as cold plate cooling, is a sophisticated cooling method wherein a cold plate is mounted directly onto the chip (GPU or CPU). The plate facilitates the transfer of heat from the chip to a circulating coolant, which then dissipates the heat. D2C cooling can be divided into two main categories: single-phase and two-phase systems, depending on the type of coolant used. Single-phase D2C typically uses a water-glycol mixture, which circulates through the system and transfers heat away from the chip via convection. This type of cooling is efficient for systems with moderate TDPs, as the coolant remains in a liquid state throughout the process. In contrast, two-phase D2C cooling uses a coolant like fluorinated refrigerant, which absorbs heat through a phase change. As the coolant transitions from liquid to gas, it provides significantly greater cooling power, making it well-suited for systems with extremely high TDPs.
The rapid increase in chip TDPs is driving the demand for more advanced cooling solutions. AI and HPC applications, in particular, are pushing the limits of current cooling technologies, as these workloads require chips with significantly higher power consumption to handle complex computations. Nvidia’s GPU roadmap, combined with Intel’s recent announcement of its Falcon Shores GPU – expected to have a TDP of 1,500W – suggests that GPUs and CPUs with TDPs exceeding 1,500W likely become common within the next one to two years. IDTechEx predicts that this ongoing rise in TDP will eventually lead to a shift from single-phase to two-phase D2C cooling systems, as the latter offers superior heat dissipation capabilities required for these high-power chips despite the unclear timeline.
In addition to direct-to-chip cooling, immersion cooling has garnered significant attention as an alternative solution for high-performance systems. Similar to D2C, immersion cooling can be split into two categories: single-phase immersion cooling (1-PIC) and two-phase immersion cooling (2-PIC). However, unlike D2C, immersion cooling involves submerging the entire server into a bath of coolant, which absorbs heat directly from all components. This method is highly effective for cooling densely packed systems with high power requirements, as it eliminates the need for air-based cooling entirely. In single-phase immersion cooling, the coolant remains in a liquid state, similar to single-phase D2C. Two-phase immersion, however, leverages a phase change in the coolant, similar to two-phase D2C, to provide even more efficient heat dissipation.
While immersion cooling offers numerous advantages in terms of thermal efficiency, it comes with several challenges. The process of submerging servers requires extensive retrofitting of existing infrastructure, as well as rigorous material compatibility tests to ensure that the components can withstand prolonged exposure to the coolant. This results in higher upfront costs compared to D2C cooling systems. Additionally, immersion cooling systems, especially two-phase variants, face regulatory challenges. For example, 3M’s Novec products, commonly used as two-phase coolants, are set to be discontinued by the end of 2025. As of now, no PFAS-free or “forever chemical”-free two-phase coolants have been officially announced, adding another layer of complexity for companies considering immersion cooling solutions.
Cooling in data centers occurs at various levels, ranging from chip-level to facility-level cooling. Each level requires different cooling strategies, with technologies like D2C and immersion cooling primarily focusing on chip, server, and rack-level thermal management. At the room and facility levels, air-based cooling remains the most common approach in 2024. Computer room air conditioning (CRAC) units and computer room air handling (CRAH) units are widely used to cool entire server rooms or data center floors. However, the growing heat loads generated by high-performance AI and HPC systems are pushing the limits of air cooling, prompting the adoption of more efficient liquid-based solutions.
One such solution is liquid-to-liquid (L2L) cooling, which is becoming increasingly popular for facility-level heat management. In L2L cooling, a cooling distribution unit (CDU) transfers heat from one liquid loop to another, enhancing heat exchange efficiency. This system is particularly effective for data centers dealing with higher heat loads from AI and HPC workloads. Supermicro’s CEO has predicted that liquid-cooled data centers, which currently represent around 1% of the market, will grow to 30% by 2026. IDTechEx shares this optimistic outlook, noting that while L2L cooling is gaining traction, its widespread adoption will likely be concentrated in newly constructed data centers due to the significant retrofitting required for existing facilities. However, many existing data centers, particularly those using CRAH units, already have facility water systems in place, which can be leveraged for L2L cooling retrofits. These existing water systems are often the starting point for upgrading older data centers to accommodate more advanced liquid cooling technologies.
In conclusion, the rapid rise of AI and HPC applications is driving a fundamental shift in data center cooling strategies. As chips like Nvidia’s B200 and Intel’s Falcon Shores GPU push the limits of thermal design power, direct-to-chip and immersion cooling solutions are becoming critical to managing the heat loads in modern data centers. This unprecedented transition brings significant opportunities to players in the data center cooling value chain, including but not limited to coolant suppliers, server makers, system integrators, cold plate manufacturers, materials suppliers, and cooling equipment (e.g., HVAC) suppliers. More details about the opportunities can be found in IDTechEx’s latest research report, “Thermal Management for Data Centers 2025-2035: Technologies, Markets, and Opportunities”.
The post The Rise of AI Drives 9 Fold Surge in Liquid Cooling Technology appeared first on HIPTHER Alerts.

Continue Reading

Trending